Galera to Host Virtual Key Opinion Leader Event on Radiotherapy-Induced Severe Oral Mucositis (SOM) in Patients with Head and Neck Cancer

Rhea-AI Summary

Galera Therapeutics (Nasdaq: GRTX) announced a virtual Key Opinion Leader event to discuss radiotherapy-induced severe oral mucositis (SOM) in head and neck cancer patients. The event is scheduled for Thursday, September 23, 2021, at 11:00 a.m. ET, featuring Dr. Carryn Anderson from the University of Iowa, alongside testimonials from survivors and insights from Galera's CEO, Mel Sorensen, M.D. The company’s lead candidate, avasopasem manganese, is in a Phase 3 ROMAN trial, expected to report results in the fourth quarter of 2021. The event will be accessible via Galera’s investor website.

Event to be webcast on Thursday, September 23 at 11:00 a.m. ET

Phase 3 ROMAN trial of avasopasem manganese, Galera’s lead candidate for SOM in patients with head and neck cancer, expected to read out in 4Q 2021

MALVERN, Pa., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that the Company will host a virtual Key Opinion Leader event on radiotherapy-induced severe oral mucositis (SOM) in patients with head and neck cancer on Thursday, September 23 at 11:00 a.m. ET.

Dr. Carryn Anderson, Clinical Associate Professor of Radiation Oncology at the University of Iowa, will provide a review of the current clinical treatment paradigm for patients with locally advanced head and neck cancer, including the use of intensity-modulated radiation therapy.

Dr. Anderson’s presentation will be followed by a video from a head and neck cancer survivor on his experience with SOM and a presentation from Galera’s President and CEO, Mel Sorensen, M.D., with an overview of the SOM market in patients with head and neck cancer.

The live audio webcast of the event will be accessible from the News & Events section of the Investors page of Galera’s website at investors.galeratx.com. Individuals can participate in an interactive Q&A session by submitting questions via the webcast platform.

An archived version of the webcast will be available for 30 days following the event.

About Galera Therapeutics

Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutic candidates that have the potential to transform radiotherapy in cancer. Galera’s lead product candidate is avasopasem manganese (avasopasem, or GC4419), a selective small molecule dismutase mimetic in late-stage development to reduce the incidence and severity of radiotherapy-induced severe oral mucositis (SOM) in patients with head and neck cancer. Avasopasem is also in development for radiotherapy-induced esophagitis in patients with lung cancer. Avasopasem has been granted FDA Fast Track and Breakthrough Therapy designations for the reduction of SOM induced by radiotherapy, with or without systemic therapy. Galera’s second dismutase mimetic product candidate, GC4711, is in clinical-stage development to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. Galera is headquartered in Malvern, PA. For more information, please visit www.galeratx.com.

Investor Contacts:
Christopher Degnan
Galera Therapeutics, Inc.
610-725-1500
cdegnan@galeratx.com

William Windham
Solebury Trout
646-378-2946
wwindham@soleburytrout.com

Media Contact:
Zara Lockshin
Solebury Trout
646-378-2960
zlockshin@soleburytrout.com 

FAQ

What is the purpose of the Galera Therapeutics event on September 23, 2021?

The event aims to discuss radiotherapy-induced severe oral mucositis (SOM) in head and neck cancer patients.

Who will present at the Galera Therapeutics Key Opinion Leader event?

Dr. Carryn Anderson will present, followed by Galera's CEO, Mel Sorensen, M.D.

When is the Phase 3 ROMAN trial for avasopasem manganese expected to read out?

The Phase 3 ROMAN trial results are expected in the fourth quarter of 2021.

How can I access the Galera Therapeutics event on radiotherapy-induced SOM?

The event will be webcast live on the Investors page of Galera's website.

What is avasopasem manganese and its significance in cancer treatment?

Avasopasem manganese is Galera's lead candidate for reducing SOM in patients undergoing radiotherapy for head and neck cancer.